Shirley He brings nine years of biostatistics experience in rare diseases and immuno-oncology, spanning early-phase through pivotal trials and regulatory submissions, including two FDA filings and one approval. Before joining Hemab Therapeutics, she served as Senior Manager of Biostatistics at Sarepta Therapeutics, leading statistical strategy for Phase 1/2 trials in Limb-Girdle Muscular Dystrophy. Her prior roles at CRISPR Therapeutics, Agios Pharmaceuticals, and Tigermed include contributions to RMAT-designated and FDA-approved programs. Shirley is skilled in SAS and R, and is currently pursuing a PhD in Biostatistics at Georgetown University.